About
Dr. Cherrington's laboratory has been focused on the effect of liver disease on the ability of an individual to metabolize and eliminate drugs, as well as the mechanisms by which drug metabolizing enzymes and transporters are regulated by cellular stress. Their early work investigating the role of cytokine signaling in cholestatic stress and the resulting alteration in drug transporter expression, and our more recent work on anti-apoptotic mechanisms of hepatoprotection led to our recent strategy of targeted therapeutic delivery to pathologic cells in the inflammatory disease state of NASH. An additional area of interest for his laboratory has been the mechanisms of altered expression and activity of the major drug metabolizing enzymes and transporters during the progressive stages of non-alcoholic fatty liver disease. They have demonstrated altered disposition of drugs in both rodents and humans diagnosed with NASH. A major thrust of this work is an effort to identify patients at greater risk of developing adverse drug reactions due to altered pharmacokinetics and overall exposure. These two areas; identifying patients with NASH and developing a therapeutic treatment for NASH, are complimentary with the mission of Research Focus Group 4 which he directs. He has also directed the Pilot Program for the SWEHSC over the past two years and takes great pride in the scientific review process provided to the internal advisory board.
INFORMATION
